VNDA NASDAQ
Vanda Pharmaceuticals Inc.
1W: -4.3%
1M: -22.8%
3M: -21.0%
YTD: -51.6%
1Y: -27.4%
3Y: -8.1%
5Y: -77.5%
$3.99
+0.05 (+1.27%)
Weekly Expected Move ±5.0%
$4
$4
$4
$4
$4
Credit Risk of going bust: higher than 65% of companies Debt: 8.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 99%), Vanda Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $22.8M against a stock market value of $241.2M.
Distance to default 3.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $11.4M (short-term plus half of long-term), stock volatility 78.5%; Altman Z'' -4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 99%), Vanda Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $22.8M against a stock market value of $241.2M.
Distance to default 3.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $11.4M (short-term plus half of long-term), stock volatility 78.5%; Altman Z'' -4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2023-12-07
Earliest Filing
2025-02-03
Latest Filing
partner: 3
investor: 1
target: 1
Counterparties (Filed by VNDA)
5 relationshipsCompanies named in VNDA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Equiniti Trust Company, LLC | — | partner | Rights agent for the Rights Agreement amendment | 2024-08-08 | View |
| Equiniti Trust Company, LLC | — | partner | Rights agent for the Rights Agreement | 2024-05-03 | View |
| BlackRock, Inc. | BLK | investor | Added as an Exempt Person under the Rights Agreement | 2024-05-03 | View |
| Actelion Pharmaceuticals Ltd. | — | target | Seller of U.S. and Canadian rights for PONVORY® (ponesimod) to Vanda Pharmaceuticals Inc. | 2023-12-07 | View |
| Johnson & Johnson | JNJ | partner | Parent company of Actelion Pharmaceuticals Ltd., the seller in the asset purchase agreement. | 2023-12-07 | View |
Mentioned As Counterparty
1 mentionsOther companies that named VNDA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-04-22 | Officer/Director Change; Exhibits | View | |
| 2026-04-02 | Officer/Director Change | View | |
| 2026-03-10 | Regulation FD Disclosure | View | |
| 2026-02-23 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-19 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2026-02-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-31 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-04 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-28 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-01 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-17 | Regulation FD Disclosure | View | |
| 2025-02-20 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR